We have located links that may give you full text access.
Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness.
American Journal of Respiratory Cell and Molecular Biology 2018 December 19
RATIONALE: Altered expression of syndecan-2, a heparan sulfate proteoglycan, has been associated with diverse types of human cancers. However, the mechanisms by which syndecan-2 may contribute to the pathobiology of lung adenocarcinoma have not been previously explored.
METHODS: Syndecan-2 levels were measured in human lung adenocarcinoma samples and Lung Cancer Tissue Microarrays using immunohistochemistry and real time-PCR. To understand the role of syndecan-2 in vitro, SDC2 was silenced or overexpressed in A549 lung adenocarcinoma cells. The invasive capacity of cells was assessed using Matrigel invasion assays and measuring matrix metalloproteinase 9 (mmp9) expression. Finally, we assessed tumor growth and metastasis of SDC2-deficient A549 cells in a xenograft tumor model.
RESULTS: Syndecan-2 expression was upregulated in malignant epithelial cells and macrophages obtained from human lung adenocarcinomas. Silencing of SDC2 decreased mmp9 expression and attenuated the invasive capacity of A549 lung adenocarcinoma cells. The inhibitory effect of SDC2 silencing on mmp9 expression and cell invasion was reversed by overexpression of mmp9 and syntenin-1. SDC2 silencing attenuated NF-κB p65 subunit nuclear translocation and its binding to the MMP9 promoter, which was restored by overexpression of syntenin-1. SDC2 silencing in vivo reduced tumor mass volume and metastasis.
CONCLUSIONS: These findings suggest that syndecan-2 plays an important role in the invasive properties of lung adenocarcinoma cells and that its effects are mediated by syntenin-1. Thus, inhibiting syndecan-2 expression or activity could serve as a potential therapeutic target to treat lung adenocarcinoma.
METHODS: Syndecan-2 levels were measured in human lung adenocarcinoma samples and Lung Cancer Tissue Microarrays using immunohistochemistry and real time-PCR. To understand the role of syndecan-2 in vitro, SDC2 was silenced or overexpressed in A549 lung adenocarcinoma cells. The invasive capacity of cells was assessed using Matrigel invasion assays and measuring matrix metalloproteinase 9 (mmp9) expression. Finally, we assessed tumor growth and metastasis of SDC2-deficient A549 cells in a xenograft tumor model.
RESULTS: Syndecan-2 expression was upregulated in malignant epithelial cells and macrophages obtained from human lung adenocarcinomas. Silencing of SDC2 decreased mmp9 expression and attenuated the invasive capacity of A549 lung adenocarcinoma cells. The inhibitory effect of SDC2 silencing on mmp9 expression and cell invasion was reversed by overexpression of mmp9 and syntenin-1. SDC2 silencing attenuated NF-κB p65 subunit nuclear translocation and its binding to the MMP9 promoter, which was restored by overexpression of syntenin-1. SDC2 silencing in vivo reduced tumor mass volume and metastasis.
CONCLUSIONS: These findings suggest that syndecan-2 plays an important role in the invasive properties of lung adenocarcinoma cells and that its effects are mediated by syntenin-1. Thus, inhibiting syndecan-2 expression or activity could serve as a potential therapeutic target to treat lung adenocarcinoma.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app